Abstract

A murine embryonic fibroblast cell line (MEF NF2-/-) was generated to model neurofibromatosis type 2 (NF2), a serious inherited disease for which there is no pharmacotherapeutic cure. Screening of a library of low-molecular-weight bioactive compounds using the experimental cell line MEF NF2-/- and MEF NF2f/f as a control cell line identified two agents, lovastatin and cerulenin, as potential candidates for NF2 pharmacotherapy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.